MaxCyte (NASDAQ:MXCT) just reported results for the first quarter of 2024.
- MaxCyte reported earnings per share of -9 cents. This was above the analyst estimate for EPS of -13 cents.
- The company reported revenue of $11.34 million.
- This was 52.04% better than the analyst estimate for revenue of $7.46 million.